Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.

The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.

Takeda has linked up with COVID-19 vaccine frontrunner Novavax, while Daiichi Sankyo has been selected by Japan’s Ministry of Health, Labour and Welfare as an official participant under the first round of a national government initiative to build production capacity.

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.